The primary question of the trial pertains to women harbouring axillary node-negative, early stage, HER2-negative, HR-positive BC who have an intermediate risk based on Oncotype DX score (RS 11–25), in whom the benefit of the addition of adjuvant chemotherapy to endocrine therapy is being investigated; the results for this cohort were published by Sparano and colleagues [32,33]. This evidence concerns the gene ERBB2 and breast cancer.